Tiago Fauth Analyst PerformanceAnalyst at Seaport Research PartnersTiago Fauth is a stock analyst at Seaport Research Partners in the healthcare sector, covering 22 publicly traded companies. Over the past year, Tiago Fauth has issued 31 stock ratings, including strong buy, buy, and sell recommendations. While full access to Tiago Fauth's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tiago Fauth's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings63 Last 6 YearsBuy Recommendations78.33% 47 Buy RatingsCompanies Covered22 Unique Companies Ratings Distribution60RatingsDistribution of strong buy, buy, hold, and sell ratings by Tiago Fauth.RatingPercentageCount Strong Buy20.0%12 ratings Buy58.3%35 ratings Hold20.0%12 ratings Sell1.7%1 ratingsOut of 60 total stock ratings issued by Tiago Fauth at Seaport Research Partners, the majority (58.3%) have been Buy recommendations, followed by 20.0% Strong Buy, 20.0% Hold, and 1.7% Sell.Best & Worst CallsBest Call0000.0%LQDAAug 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%WVESep 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ22 companiesTiago Fauth, an analyst at Seaport Research Partners, currently covers 22 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare22 companies100.0%Tiago Fauth of Seaport Research Partners specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY18 companies81.8%PHARMACEUTICALS4 companies18.2% Tiago Fauth's Ratings History at Seaport Research Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSPTXSeaport Therapeutics9/25/2026Initiated Coverage$21.12$46.00Strong-Buy$0.0000.00% ROISPTXSeaport Therapeutics9/25/2026Set Price Target$21.12$46.00$0.0000.00% ROISPTXSeaport Therapeutics9/25/2026Initiated Coverage$21.52$46.00Strong-Buy$0.0000.00% ROIRAPPRapport Therapeutics9/22/2026Reiterated Rating$41.47Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/8/2026Reiterated Rating$56.40$84.00Outperform$0.0000.00% ROIRAPPRapport Therapeutics8/17/2026Reiterated Rating$47.42$75.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics8/14/2026Set Price Target$11.36$31.00$0.0000.00% ROIPLYXPolaryx Therapeutics8/13/2026Initiated Coverage$2.23$6.00Strong-Buy$0.0000.00% ROITNXPTonix Pharmaceuticals8/10/2026Reiterated Rating$12.50$27.00Strong-Buy$0.0000.00% ROITECXTectonic Therapeutic8/7/2026Lower Price Target$31.37$93.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IONSIonis Pharmaceuticals7/9/2026Set Price Target$64.51$87.00$0.0000.00% ROITNXPTonix Pharmaceuticals6/24/2026Initiated Coverage$12.10$26.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics6/24/2026Initiated Coverage$30.65$46.00Strong-Buy$0.0000.00% ROIMPLTMaplight Therapeutics6/24/2026Upgrade$31.96Strong-Buy$0.0000.00% ROITNXPTonix Pharmaceuticals6/24/2026Upgrade$11.98Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/10/2026Initiated Coverage$75.28$104.00Outperform$0.0000.00% ROIPTCTPTC Therapeutics4/10/2026Initiated Coverage$70.85$108.00Outperform$0.0000.00% ROIRAPPRapport Therapeutics4/10/2026Initiated Coverage$34.22$66.00Strong-Buy$0.0000.00% ROIPTCTPTC Therapeutics4/9/2026Initiated Coverage$68.69Moderate Buy$0.0000.00% ROIRAPPRapport Therapeutics4/9/2026Initiated Coverage$34.17Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/9/2026Upgrade$76.76Moderate Buy$0.0000.00% ROIINSMInsmed12/16/2025Boost Price Target$196.92$234.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics11/5/2025Boost Price Target$67.72$93.00Overweight$0.0000.00% ROIINSMInsmed10/31/2025Boost Price Target$194.22$217.00Overweight$0.0000.00% ROIINSMInsmed10/20/2025Initiated Coverage$165.76$171.00Overweight$0.0000.00% ROILQDALiquidia10/20/2025Initiated Coverage$22.48$31.00Overweight$0.0000.00% ROIMNKDMannKind10/20/2025Initiated Coverage$5.47$10.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics10/20/2025Initiated Coverage$65.95$73.00Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical10/20/2025Initiated Coverage$32.63$65.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics10/20/2025Initiated Coverage$433.34$414.00Underweight$0.0000.00% ROIWVEWAVE Life Sciences10/20/2025Initiated Coverage$7.81$18.00Overweight$0.0000.00% ROIWVEWAVE Life Sciences9/4/2025Lower Price Target$8.00$18.00Overweight$0.0000.00% ROIINSMInsmed9/3/2025Boost Price Target$145.30$171.00Overweight$000.0000.00% ROIUTHRUnited Therapeutics9/3/2025Boost Price Target$404.27$414.00Equal Weight$000.0000.00% ROIMNKDMannKind9/3/2025Boost Price Target$5.63$10.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics8/20/2025Lower Price Target$48.30$73.00Overweight$00.0000.00% ROILQDALiquidia8/13/2025Boost Price Target$24.10$31.00Overweight$00.0000.00% ROIINSMInsmed8/12/2025Boost Price Target$122.00$140.00Overweight$000.0000.00% ROIPTCTPTC Therapeutics8/8/2025Boost Price Target$46.28$79.00Overweight$00.0000.00% ROIALNYAlnylam Pharmaceuticals8/1/2025Boost Price Target$395.93$395.00Equal Weight$000.0000.00% ROIALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.See the 5 stocks to avoidWVEWAVE Life Sciences7/31/2025Lower Price Target$8.32$21.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics7/31/2025Lower Price Target$278.91$295.00Equal Weight$000.0000.00% ROIPTCTPTC Therapeutics7/29/2025Boost Price Target$48.86$78.00Overweight$00.0000.00% ROIINSMInsmed7/22/2025Boost Price Target$103.27$130.00Overweight$000.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share7/10/2025Downgrade$104.77$107.00Hold$0.0000.00% ROIRAREUltragenyx Pharmaceutical7/10/2025Lower Price Target$30.25$65.00Overweight$00.0000.00% ROIBBIOBridgeBio Pharma6/30/2025Boost Price Target$44.24$76.00Overweight$00.0000.00% ROIALNYAlnylam Pharmaceuticals6/30/2025Boost Price Target$324.99$333.00Equal Weight$000.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share6/20/2025Boost Price Target$90.92$138.00Overweight$0.0000.00% ROIINSMInsmed6/11/2025Boost Price Target$90.93$119.00Overweight$00.0000.00% ROIPTCTPTC Therapeutics5/27/2025Boost Price Target$45.93$74.00Overweight$00.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share4/30/2025Boost Price Target$72.46$107.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics4/25/2025Reiterated Rating$296.42$314.00Equal Weight$000.0000.00% ROIALNYAlnylam Pharmaceuticals3/21/2025Boost Price Target$253.60$287.00Equal Weight$000.0000.00% ROITECXTectonic Therapeutic3/21/2025Lower Price Target$20.58$101.00Overweight$00.0000.00% ROIKROSKeros Therapeutics2/27/2025Lower Price Target$11.35$26.00Overweight$00.0000.00% ROIFOLDAmicus Therapeutics2/20/2025Lower Price Target$9.56$17.00Overweight$00.0000.00% ROIINSMInsmed2/19/2025Boost Price Target$81.36$107.00Overweight$000.0000.00% ROIPLRXPliant Therapeutics2/10/2025Downgrade$7.79$4.00Equal Weight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
